Data from a hospital-based case-control study were analyzed to evaluate the relation of adult height to the risk of breast cancer among white women. The authors compared 5,358 newly diagnosed breast cancer cases and 4,555 controls interviewed from 1976 to 1992 in hospitals located mainly in the United States. Overall, there was no association between stature and nsk of breast cancer. In comparison with women whose heights were less than 62 inches (< 158 cm), the adjusted odds ratios were 1.1 (95% confidence interval (Cl) 0.9-1.2), 1.0 (95% Cl 0.9-1.2), 1.0 (95% Cl 0.9-1.1), and 1.0 (95% Cl 0.8-1.2) for women with heights of 62-63, 64-65, 66-67, and >68 inches (equivalent to 158-160,163-165,168-170, and 2173 cm), respectively. There was no consistent evidence of modification of the effect of height by other risk factors. The results suggest that adult stature in white women is not related to the risk of breast cancer. Am J Epidemiol 1996;143:1123-8. body height; breast neoplasms; contraceptives, oral A variety of body build indicators, such as weight, height, and body mass index, have been examined in studies of breast cancer. During the past several decades, research has focused primarily on weight or body mass index, and the effect of these factors appears to vary according to the woman's menopausal status: Modest positive associations have been found among postmenopausal women, while an inverse relation has sometimes been present among premenopausal women (1).
A variety of body build indicators, such as weight, height, and body mass index, have been examined in studies of breast cancer. During the past several decades, research has focused primarily on weight or body mass index, and the effect of these factors appears to vary according to the woman's menopausal status: Modest positive associations have been found among postmenopausal women, while an inverse relation has sometimes been present among premenopausal women (1) .
The effect of height on the risk of breast cancer has been less thoroughly investigated, and the epidemiologic evidence does not indicate a convincing association (2, 3) . In some studies, tallness is associated with a modest increased risk of breast cancer, especially among postmenopausal women, but other studies have reported no association of stature with risk. Few studies (4) (5) (6) (7) (8) have examined whether a relation of height to the risk of breast cancer is modified by other risk factors, and the findings have been inconsistent.
We analyzed data from a hospital-based casecontrol study to evaluate the relation of adult height to breast cancer risk in white women, and to explore whether the effect of height could be modified by other breast cancer risk factors.
MATERIALS AND METHODS
Since 1976, a case-control drug surveillance study has been conducted in hospitals located in several geographic regions of the United States (the cities of Boston, New York, Philadelphia, Baltimore, San Francisco, and Tucson and the state of Kansas) and in Canada and Israel (9) . Over 90 percent of patients were interviewed in the first four US cities. The participating hospitals, which change from time to time, include teaching, cancer, and community hospitals. Specially trained nurse-interviewers identify and interview women admitted for breast cancer and for a wide range of other conditions. A standard questionnaire is used to obtain information on personal characteristics, relevant medical history, and history of medication use. After discharge, each patient's diagnoses, including the primary diagnosis that led to hospital admission, are abstracted from the hospital record. White women interviewed through March 31, 1992 , were included in the present study. Ninety-two percent of the women were from the United States, and 8 percent were from Israel. Of the patients approached, approximately 4 percent refused to be interviewed.
Selection of cases
White women aged 20-69 years who met the following criteria were included in the case series: a diagnosis of breast cancer recorded in the discharge summary or pathology report (10) that had been made within 1 year before the current admission, and no other primary cancer or history of cancer. Virtually all of the women were identified when they were admitted for treatment of the cancer. Of 5,383 case women, information on adult height was available from 5,358 (99.5 percent), who comprised the final case series. Of the latter, 5,127 (96 percent) had been diagnosed within the preceding 6 months; the median age was 51 years, and 82 cases (1.6 percent) were under 30 years of age. Almost all of the case women (97 percent) were from the United States.
Selection of controls
Controls were selected from a pool of approximately 25,000 white women aged 20-69 years who had been admitted for nonmalignant conditions and who had no history of cancer. We excluded women who were admitted for diseases judged to be related to height or weight, such as endocrine, nutritional, and metabolic diseases, and for diseases related to pregnancy, childbirth, and the puerperium. Women were also excluded if their primary diagnosis was hypertension, ischemic heart disease, back pain, a disc disorder, another orthopedic problem, or trauma, since some studies (11, 12) have suggested that these diseases may be associated with stature.
There were 9,018 controls remaining after the exclusions. The median age was 45 years, and 22.5 percent were under age 30. To attain more comparable age and geographic distributions between cases and controls, we selected a subset of the controls using frequency matching. For each case stratum defined by 5-year age category and geographic region of the hospitals (New York City, Boston, Philadelphia, Baltimore, San Francisco, Tucson, Kansas, and Israel), we randomly selected up to twice as many controls as cases. The final control series totaled 4,555 women; the median age was 47 years, and 68 (1.5 percent) were under 30 years of age.
The final control group included women with diseases of the digestive system (15.3 percent); diseases of the genitourinary system (12.1 percent); diseases of skin, muscle, and bone (15.9 percent); accidents (21.4 percent); and other conditions (35.3 percent).
Exposure and potentially confounding factors
All participants were interviewed in the hospital after they had given informed consent. Height was reported to the nearest inch or centimeter. Most participants reported their height in inches; thus, we used these units rather than metric values in the analyses. Data were also collected on many potential risk factors for breast cancer, including years of education, religion, age at menarche, menopausal status, age at first pregnancy, parity, history of benign breast disease, history of breast cancer in a mother or sister, oral contraceptive use, estrogen use, smoking, and alcohol consumption.
Analysis
We divided the subjects into five height categories: <62, 62-63, 64-65, 66-67, and >68 inches (equivalent to <158, 158-160, 163-165, 168-170, and >173 cm). A height of less than 62 inches was the reference category for relative risk estimation. The relative risk (odds ratio) of breast cancer was estimated by multiple logistic regression. In addition to variables for the height groups, the regression models included indicator terms for age, year of interview, geographic area, religion, education, current body mass index (weight (kg)/height squared (m 2 )), age at menarche, menopausal status, age at first pregnancy, parity, history of benign breast disease, family history of breast cancer, oral contraceptive use, conjugated estrogen use, alcohol use, and cigarette smoking. To test for a trend in risk, we included a continuous term for height in the multivariate model.
To test whether the relation between height and breast cancer risk was modified by other risk factors, we stratified the subjects according to levels of each risk factor and used multiple logistic regression to obtain estimates of relative risk for height categories within strata. Interaction terms for height and particular risk factors were used in the regression model to test for statistical significance. Table 1 shows the age-standardized height distribution for different disease categories among the controls. Most disease categories had similar height distributions, with the percentages for the lowest height category ranging from 13.3 percent to 14.4 percent and those for the tallest height category ranging from 8.9 percent to 12.3 percent.
RESULTS
We examined the age-standardized distribution of heights according to breast cancer risk factors in the controls. Short stature was associated with earlier years of interview, living in Israel, fewer years of education, Jewish religion, earlier year of birth, greater current body mass index, earlier age at menarche, earlier age at first pregnancy, no family history of breast cancer, and abstinence from alcohol drinking; it was inversely associated with nulliparity. There was little relation with menopausal status, benign breast disease, oral contraceptive use, estrogen use, and cigarette smoking, and there was an inconsistent relation with body mass index at age 20. Table 2 gives relative risk estimates (odds ratios) according to height. All risk estimates were close to 1.0. There was no indication of an increase in breast cancer risk with increasing height (p for trend = 0.31). Compared with women in the shortest height category (<62 inches), the crude odds ratio for breast cancer among women in the tallest height category (^68 inches) was 0.9. With adjustment for age, geographic area, and major breast cancer risk factors, the risk estimate was 1.0 (95 percent confidence interval 0.8-1.2).
Relations between height and breast cancer risk within categories of the other factors are shown in table 3. There was little evidence for an association between breast cancer risk and height within categories of geographic region, age at menarche, menopausal status, age at first pregnancy, parity, history of benign breast disease, family history of breast cancer, and conjugated estrogen use. Statistically significant inverse associations between height and breast cancer risk were found in some categories (such as women interviewed in Boston, women with body mass indices over 29 at interview, and women over 30 years of age at first pregnancy), but there were no consistent patterns within other categories of those variables. There was a statistically significant trend of increasing risk of breast cancer with increasing height among oral contraceptive users, and a significant trend of decreasing risk among nonusers. hi the multiple logistic regression model, the interaction term for height and oral contraceptive use was statistically significant relative risk estimates for all height categories were (p < 0.001).
DISCUSSION
The results of the present study, conducted mainly among US white women, suggest that height has little if any relation to the risk of breast cancer. The adjusted close to 1, and this was generally the case within most levels of other risk factors.
There were a few statistically significant associations when we examined height within categories of breast cancer risk factors. For example, the relation appeared to be modified by oral contraceptive use.
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Among users of oral contraceptives, the risk of breast cancer increased as stature increased; however, an inverse association was observed among nonusers. The finding could well be attributable to chance.
To date, the epidemiologic evidence on the relation of height to the risk of breast cancer has not been conclusive (3) . A positive correlation between adult height and breast cancer incidence has been observed in several international correlational studies (13) (14) (15) , and results from many analytical epidemiologic studies (4) (5) (6) (7) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) have also indicated such an association. On the other hand, conflicting results have been observed in many other studies (8, 24, (31) (32) (33) (34) (35) (36) (37) (38) . Of 10 studies of US Caucasian women in which the relation of height to breast cancer risk was reported (17, 19, 28, 29, (31) (32) (33) (34) (35) (36) , four (17, 19, 28, 29) have found a positive association.
A biologic mechanism for a link between height and breast cancer risk in women has not been well established. A proposed explanation is that high energy intake during childhood and adolescence is related to larger adult body size and earlier maturation of ovarian function, and that these factors, in turn, are associated with the risk of breast cancer (39). London et al. (32) suggested that the inconsistent results might be due to variability in early nutritional status in the study populations. Indeed, the positive findings were often seen in the studies in which some women had experienced nutritional deprivation early in life (19) (20) (21) (22) . Consistent with this possibility is the fact that, in data collected from African-American women in the same study as the present study of white women, short stature was related to reduced risk (20) . Black women have experienced greater poverty levels than white women, and this may be reflected in their energy balance in childhood. However, in most industrialized countries, variability of height probably predominantly reflects genetic factors rather than differences in early nutritional status. Positive associations have also been reported in some studies of US white women, among whom there is unlikely to have been severe nutritional deprivation (17, 28, 29) .
The conflicting results on the relation of height to breast cancer have mostly been seen in case-control studies. Selection bias may have contributed to the inconsistent findings. In most case-control studies that reported an association between height and risk of breast cancer, the major objective was not to test the relation of stature to risk. In those studies, especially the hospital-based case-control studies, the controls might have been satisfactory for testing the primary hypothesis but not have been a valid comparison group with which to assess the effect of height, because adult height appears to be related to the risk of some other diseases (11, 12) .
The main objective of the present analysis was to evaluate the relation between height and breast cancer risk. Potential controls were carefully selected from women whose diagnoses were unrelated to height. The height distributions were similar across the different geographic areas within the United States. They were also similar across a range of diagnostic categories, including diagnoses for which admission to a hospital is usually obligatory and, therefore, less susceptible to selection bias. With regard to selection bias in the case series, referral patterns for cases and controls may have differed. However, the results were consistent across geographic regions, each of which had a different mix of teaching, cancer, and community hospitals. Further evidence against material selection bias is the fact that the relations of other major risk factors to breast cancer risk in the present data are consistent with other investigators' reports (9) . Nevertheless, we are unable to rule out the possibility that selection bias might account for the findings.
Participants in the present study were not measured by the interviewers, and we were unable to validate the self-reported information. Self-reported height is fairly accurate, but some studies (40, 41) have shown a tendency for short women to overstate their height. However, there is no reason to suspect that women with breast cancer would understate or overstate their height differently from controls.
Important breast cancer risk factors were controlled simultaneously in multivariate analysis. The estimates of effect of height derived from these analyses were similar to crude ones, suggesting that there was little if any confounding from the major breast cancer risk factors.
In summary, the present study found no association between adult stature and risk of breast cancer among white women.
